Rein Therapeutics says that the US Patent and Trademark Office (USPTO) has recently granted US Patents No. 12,280,088 and No. 12,280,089, which cover the dry powder peptide formulation of the company’s lead candidate, LTI-03. Both of the new patents are titled “Dry Powder Formulation of Caveolin-1 Peptides and Methods of Use Thereof.”
Rein President and CEO Brian Windsor commented, “These new patents strengthen the proprietary foundation of our inhaled peptide program and support the continued development of LTI-03 as a potential first-in-class therapeutic option for the treatment of IPF and other chronic and acute lung conditions. We believe that our dual-mechanism approach has the potential to address the significant unmet need in this patient population, and we look forward to initiating our Phase 2 clinical trial of LTI-03 in patients with IPF in the first half of this year.”
Read the Rein Therapeutics press release
